Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

652

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone palmitate 25 mg eq.

Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64

DRUG

Paliperidone palmitate 150 mg eq.

Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64

DRUG

Placebo

Placebo i.m. Days 1, 8, 36, 64

DRUG

Paliperidone palmitate 100 mg eq.

Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64

Trial Locations (66)

Unknown

Anaheim

Cerritos

Escondido

Glendale

La Palma

Los Angeles

National City

San Diego

Santa Ana

Jacksonville

Kissimmee

Miami

North Miami

Atlanta

Hoffman Estates

Kingsport

Wichita

Lake Charles

Shreveport

Baltimore

Rockville

Cedarhurst

New York

Olean

Cincinnati

Moore

Charleston

Austin

Houston

San Antonio

Arlington

Richmond

Johor Bahru

Kota Bharu

Kuala Lumpur

Perak

Brasov

Bucharest

Craiova

Iași

Oradea

Sibiu

Tg Mures

Kazan'

Lipetsk

Moscow Russia

Nizny Novgorod

Saint Petersburg

Samara

St-Petersburg Na

St-Petresburg

Yaroslavl

Belgrade

Kragujevac

Gwangju

Inchun

Seoul

Changhua

Hualien City

Kaohsiung City

Taipei

Dnipro

Kharkiv

Kiev

Odesa

Simferopol

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00590577 - Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter